Outcome of Board Meeting held on 04th May 2026
NATHBIOGEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
The Board approved the standalone audited financial results for FY 2025-26 ending 31st March 2026. Revenue from operations grew by 19.1% to Rs 43,159.72 Lakhs from Rs 36,230.81 Lakhs in the previous year. Net profit increased to Rs 4,442.57 Lakhs (up 5.4% from Rs 4,214.01 Lakhs). The company declared a dividend of Rs 2 per share (20%) subject to shareholder approval. The auditors issued an unmodified (clean) opinion with two Emphasis of Matter notes: (1) recovery of Rs 600.73 Lakhs against previously provisioned doubtful advances to farmers/growers, and (2) pending confirmations on trade receivables, payables, and loans. The Board reappointed Mr. Hitesh Purohit as Independent Director for five years, appointed M/s K.P. Sahasrabudhe & Co. as Internal Auditor, and increased MD remuneration from Rs 66 Lakhs to Rs 144 Lakhs per annum.
Revenue growth is strong at 19.1% but PAT growth is modest at 5.4%, indicating margin pressure. The negative operating cash flow of Rs 1,391.44 Lakhs (versus positive Rs 2,679.85 Lakhs last year) raises concerns about cash generation ability despite healthy profitability. The clean audit opinion is positive.